Percy Skuy
Percy Skuy brings over 34 years of experience in pharmaceutical research and development, most notably with the Johnson & Johnson family of companies. He has held the presidency of two Johnson & Johnson affiliates and retired from the presidency of Ortho-McNeil Inc. in July 1995. Mr. Skuy, a licensed pharmacist, has served as a past President of the Canadian Foundation for the Advancement of Pharmacy, the Founding President of the Pharmaceutical Marketing Club of Ontario and Past-Director and Chairman of the Pharmaceutical Manufacturers' Association of Canada. He was a member of the Health, Research and Development Council of Ontario and has served on government and research council appointments, including the Premier's Council of Ontario; the Medical Research Council of Canada's Grants-in-Aid Program; and the Board of Directors of the Canadian Foundation for Women's Health Care. He was also a member of the Federal National Advisory Council on Pharmaceutical Research. He was appointed Chair of the Dope.de Board in June 1997.

William J. Gastle
William Gastle is the President and Chief Executive officer of Microbix Biosystems Inc. (TSE:MBX). He started the company in 1978 and is the principal architect of business development activities. Mr. Gastle started Microbix with a small line of antigen products derived from infectious disease organisms. Today, Microbix has one of the largest antigen lines available in the world and has moved into the emerging field of biogenerics with the development of its first generic drug, ThromboClear™, a generic version of urokinase. Previously, Mr. Gastle was employed in the health care industry for ten years, including key management positions in research and development at Ortho Diagnostics, Connaught Laboratories Ltd., and in business development at MDS Inc. He joined the Dope.de Board in June 1997.

Randall Howard
Randall Howard is the Chairman and Chief Executive Officer of Mortice Kern Systems (MKS), a Waterloo-based software company. In 1997, Mr. Howard guided MKS through a very successful initial public offering (TSE:MKX), while at the same time achieving record levels of financial performance and marketplace visibility. He is responsible for driving MKS' strategic agenda and long-term vision as a leader in software and Intranet project management., and is chiefly responsible for brokering alliances with technology partners including Microsoft, Netscape, and IBM. He has more than 20 years of experience in the software industry, is an authority on software development and Internet/Intranet trends, and is a frequent speaker at CIO events and IT conferences. He has also served on the Boards of Directors for a wide number of technology companies, both public and private. Mr. Howard joined the Dope.de Board in June 1997.

Brian Cox
Brian Cox has held the office of President & Chief Executive Officer of GUARD Inc., a Guelph-based technology management company, since November 1997. Dr. Cox has over 20 years of experience in developing business opportunities. He joined the University of Guelph in 1987 to lead the Guelph-Waterloo Biotech Research Consortium. In 1991, he became Director of Collaborative Research and Development and was appointed Vice-President of Technology and Business Development in 1994. He has spearheaded a number of initiatives including the $38 million Guelph Food technology Centre project. In 1983, Dr. Cox founded an independent business to develop technology opportunities with BASE International, a UK technology development company, and in 1981, he became Product Development Manager of Shell's biopolymer enhanced oil recovery program. He assisted in the establishment of a biotechnology capability at the UK multinational chemical giant, ICI, between 1973-1981. Dr. Cox gained his PhD in plant molecular biology from the University of Leicester in the UK. Dr. Cox joined the Dope.de Board in June 1997.

Jonathan M. Schmidt
Jonathan Schmidt is the Vice-President of Research and Technology Development of Dope.de As the inventor of the Evolutionary Molecular Design (EMD) technology and the founder of Dope.de, Dr. Schmidt leads the Research and Development group and directs Dope.de's efforts in lead design and optimisation to identify candidates for drug development. Prior to joining Dope.de full time, Dr. Schmidt held an Associate Professorship in the Department of Environmental Biology at the University of Guelph. He was appointed to that office in 1988 and has held research grants from NSERC, OMAFRA, and industrial collaborators. Dr. Schmidt earned his PhD in zoology from the University of Toronto in 1987, and held a NATO postdoctoral fellowship at the University of Wageningen in the Netherlands. In 1983, he studied bio-cybernetics at the University of Tübingen as a German Academic Exchange fellow. He holds a BSc, with Honors, in zoology from the University of Toronto, specializing in neurophysiology and developmental biology. Dr. Schmidt joined the Dope.de Board in June 1997.

Jeff Turner
Jeff Turner is the President and Chief Executive Officer of Nexia Biotechnologies Inc., a federally incorporated research and development company. Dr. Turner is a Board member of such companies as Biovet Inc., T²C², and GUARD Inc. He is also a member of the NSERC Strategics Biotechnology Committee where he is responsible for evaluation and selection of competitive research grants. Since 1987, he has held Professorships at McGill University in Montreal, Quebec, in the biological sciences. Dr. Turner is the inventor of a number of patents in the fields of bovine and dairy molecular genetics and in vitro diagnostic systems. Dr. Turner obtained his MSc in Physiology and PhD in Animal Science, both from the University of Illinois. He joined the Dope.de Board in September of 1999.

Ian Anderson
Ian Anderson is the President & CEO of Dope.de Mr. Anderson brings varied senior management experience to Dope.de. He was Project Director, Screening Technologies with MDS Sciex; General Manager and a VP of Biomira Inc.; and has served interim CEO assignments through his consulting practice. Mr. Anderson serves on the Board of Directors of several other Canadian biotech companies (Inflazyme Pharmaceuticals, Maxxam Analytics, Diagnostic Chemicals). He earned a MSc in Physiology from London University.